These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 26719217)

  • 21. Complex regulation of CDKs and G1 arrest during the granulocytic differentiation of human myeloblastic leukemia ML-1 cells.
    Shimizu T; Awai N; Takeda K
    Oncogene; 2000 Sep; 19(40):4640-6. PubMed ID: 11030153
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activation of the cyclin D2 and cdk6 genes through NF-kappaB is critical for cell-cycle progression induced by HTLV-I Tax.
    Iwanaga R; Ozono E; Fujisawa J; Ikeda MA; Okamura N; Huang Y; Ohtani K
    Oncogene; 2008 Sep; 27(42):5635-42. PubMed ID: 18504428
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The history and future of targeting cyclin-dependent kinases in cancer therapy.
    Asghar U; Witkiewicz AK; Turner NC; Knudsen ES
    Nat Rev Drug Discov; 2015 Feb; 14(2):130-46. PubMed ID: 25633797
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of the melanoma cell cycle and regulation at the G1/S transition by 12-O-tetradecanoylphorbol-13-acetate (TPA) by modulation of CDK2 activity.
    Coppock DL; Buffolino P; Kopman C; Nathanson L
    Exp Cell Res; 1995 Nov; 221(1):92-102. PubMed ID: 7589260
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential regulation of retinoblastoma tumor suppressor protein by G(1) cyclin-dependent kinase complexes in vivo.
    Ezhevsky SA; Ho A; Becker-Hapak M; Davis PK; Dowdy SF
    Mol Cell Biol; 2001 Jul; 21(14):4773-84. PubMed ID: 11416152
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting Cyclin-Dependent Kinases in Ovarian Cancer.
    Zhou Q
    Cancer Invest; 2017 Jul; 35(6):367-376. PubMed ID: 28406716
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cyclin-dependent kinase 6 inhibits proliferation of human mammary epithelial cells.
    Lucas JJ; Domenico J; Gelfand EW
    Mol Cancer Res; 2004 Feb; 2(2):105-14. PubMed ID: 14985467
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glucocorticoids induce G1 as well as S-phase lengthening in normal human stimulated lymphocytes: differential effects on cell cycle regulatory proteins.
    Baghdassarian N; Catallo R; Mahly MA; Ffrench P; Chizat F; Bryon PA; Ffrench M
    Exp Cell Res; 1998 May; 240(2):263-73. PubMed ID: 9596999
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Control of G1 progression by D-type cyclins: key event for cell proliferation.
    Kato JY
    Leukemia; 1997 Apr; 11 Suppl 3():347-51. PubMed ID: 9209386
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased expression of p27Kip1 arrests neuroblastoma cell growth.
    Matsuo T; Seth P; Thiele CJ
    Med Pediatr Oncol; 2001 Jan; 36(1):97-9. PubMed ID: 11464914
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors.
    Pavletich NP
    J Mol Biol; 1999 Apr; 287(5):821-8. PubMed ID: 10222191
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging role of NF-κB signaling in the induction of senescence-associated secretory phenotype (SASP).
    Salminen A; Kauppinen A; Kaarniranta K
    Cell Signal; 2012 Apr; 24(4):835-45. PubMed ID: 22182507
    [TBL] [Abstract][Full Text] [Related]  

  • 33. p16(INK4a) exerts an anti-inflammatory effect through accelerated IRAK1 degradation in macrophages.
    Murakami Y; Mizoguchi F; Saito T; Miyasaka N; Kohsaka H
    J Immunol; 2012 Nov; 189(10):5066-72. PubMed ID: 23066149
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lead activates nuclear transcription factor-kappaB, activator protein-1, and amino-terminal c-Jun kinase in pheochromocytoma cells.
    Ramesh GT; Manna SK; Aggarwal BB; Jadhav AL
    Toxicol Appl Pharmacol; 1999 Mar; 155(3):280-6. PubMed ID: 10079214
    [TBL] [Abstract][Full Text] [Related]  

  • 35. P16Ink4a tumor suppressor function in lung cancer cells involves cyclin-dependent kinase 2 inhibition by Cip/Kip protein redistribution.
    Grimison B; Langan TA; Sclafani RA
    Cell Growth Differ; 2000 Oct; 11(10):507-15. PubMed ID: 11063124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activation of cyclin D1-kinase in murine fibroblasts lacking both p21(Cip1) and p27(Kip1).
    Sugimoto M; Martin N; Wilks DP; Tamai K; Huot TJ; Pantoja C; Okumura K; Serrano M; Hara E
    Oncogene; 2002 Nov; 21(53):8067-74. PubMed ID: 12444543
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mitoinhibitory effects of the tumor promoter 2-acetylaminofluorene in rat liver: loss of E2F-1 and E2F-3 expression and cdk 2 kinase activity in late G1.
    Ohlson LC; Koroxenidou L; Porsch-Hällström I
    J Hepatol; 2004 Jun; 40(6):957-62. PubMed ID: 15158336
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Downregulation of cyclin D1 alters cdk 4- and cdk 2-specific phosphorylation of retinoblastoma protein.
    Yu B; Lane ME; Pestell RG; Albanese C; Wadler S
    Mol Cell Biol Res Commun; 2000 Jun; 3(6):352-9. PubMed ID: 11032757
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21.
    Li Y; Jenkins CW; Nichols MA; Xiong Y
    Oncogene; 1994 Aug; 9(8):2261-8. PubMed ID: 7913544
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modulation of p27(Kip1) levels by the cyclin encoded by Kaposi's sarcoma-associated herpesvirus.
    Mann DJ; Child ES; Swanton C; Laman H; Jones N
    EMBO J; 1999 Feb; 18(3):654-63. PubMed ID: 9927425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.